Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited ChoicesMADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal ...